GAIN THERAPEUTICS, INC Operating Lease, Expense
GAIN THERAPEUTICS, INC (GANX) reported Operating Lease, Expense of $185.50 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2024-11-14
- GAIN THERAPEUTICS, INC operating lease, expense for the quarter ending 2024-09-30 was $61.59K, a 0.42% decline year-over-year.
- GAIN THERAPEUTICS, INC operating lease, expense for the quarter ending 2024-06-30 was $61.26K, a 0.43% decline year-over-year.
- GAIN THERAPEUTICS, INC operating lease, expense for the quarter ending 2024-03-31 was $62.66K, a 3.39% increase year-over-year.
- GAIN THERAPEUTICS, INC operating lease, expense for the quarter ending 2023-12-31 was $62.19K, a 6.31% increase year-over-year.
- GAIN THERAPEUTICS, INC operating lease, expense for fiscal 2023 was $246.16K, a 7.62% increase from fiscal 2022.
- GAIN THERAPEUTICS, INC operating lease, expense for fiscal 2022 was $228.74K, a 19.55% increase from fiscal 2021.
- GAIN THERAPEUTICS, INC operating lease, expense for fiscal 2021 was $191.33K, a 57.08% increase from fiscal 2020.
- GAIN THERAPEUTICS, INC operating lease, expense for fiscal 2020 was $121.80K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2024-09-30 | $61.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $122.85K derived: sum of 2 quarters · filed 2024-11-14 | $185.50K 10-Q · filed 2024-11-14 | $247.69K derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | $61.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $123.92K 10-Q · filed 2024-08-08 | $186.10K derived: sum of 3 quarters · filed 2024-08-08 | $247.95K derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-03-31 | $62.66K 10-Q · filed 2024-05-14 | $124.85K derived: sum of 2 quarters · filed 2024-05-14 | $186.69K derived: sum of 3 quarters · filed 2024-11-14 | $248.22K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-12-31 | $62.19K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $124.04K derived: sum of 2 quarters · filed 2024-11-14 | $185.56K derived: sum of 3 quarters · filed 2024-11-14 | $246.16K 10-K · filed 2024-03-26 |
| 2023-09-30 | $61.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $123.38K derived: sum of 2 quarters · filed 2024-11-14 | $183.98K 10-Q · filed 2024-11-14 | $242.47K derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $61.53K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $122.13K 10-Q · filed 2024-08-08 | $180.63K derived: sum of 3 quarters · filed 2024-08-08 | $238.40K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $60.60K 10-Q · filed 2024-05-14 | $119.10K derived: sum of 2 quarters · filed 2024-05-14 | $176.87K derived: sum of 3 quarters · filed 2024-05-14 | $231.17K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $58.50K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $116.27K derived: sum of 2 quarters · filed 2024-03-26 | $170.57K derived: sum of 3 quarters · filed 2024-03-26 | $228.74K 10-K · filed 2024-03-26 |
| 2022-09-30 | $57.77K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $112.07K derived: sum of 2 quarters · filed 2023-11-14 | $170.24K 10-Q · filed 2023-11-14 | $227.97K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $54.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $112.47K 10-Q · filed 2023-08-10 | $170.19K derived: sum of 3 quarters · filed 2023-08-10 | $221.93K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $58.17K 10-Q · filed 2023-05-12 | $115.89K derived: sum of 2 quarters · filed 2023-05-12 | $167.64K derived: sum of 3 quarters · filed 2023-05-12 | $211.28K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $57.73K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $109.47K derived: sum of 2 quarters · filed 2023-03-23 | $153.10K derived: sum of 3 quarters · filed 2023-03-23 | $191.33K 10-K · filed 2023-03-23 |
| 2021-09-30 | $51.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $95.38K derived: sum of 2 quarters · filed 2022-11-10 | $133.60K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $43.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $81.86K 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $38.22K 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $121.80K 10-K · filed 2022-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |